hotspot -WSS

hotspot

author：hotspot 2025-09-27 16:35:58 - browse：697

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： People with substance use disorder deserve online privacy

WSS

Kenai launches with $82 million for Parkinson’s stem cell therapy

Biotech companies concerned about China biosecurity crackdown

'A game

Covid’s new normal has set in amid another rise in cases

Senate bill would ban some hospital facility fees

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

hotspot

hotspot

hotspot

Medical records are filled with copy

How the messy conversation about Dolly changed bioethics

ChatGPT in medicine: STAT answers readers' burning questions

David Liu startup to focus on CRISPR delivery

Moonlake's readout produced a cash windfall. Risks remain

ALS groups 'won't be played again' by the FDA, drug sponsors

Bright Health sells Medicare Advantage business to Molina

Medicare to pay more for cardiac rehab in hospital outpatient clinics

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Patients, doctors press FTC to beef up hospital merger scrutiny

leisure time

Medical device lobby: We're tired of waiting on Medicare coverage

David Liu startup to focus on CRISPR delivery

Kenai launches with $82 million for Parkinson’s stem cell therapy

House looks to weaken Medicare negotiation

David Liu startup to focus on CRISPR delivery

International team creates first chimeric human

explore

hotspot

hotspot

hotspot